Ainos, Inc. (AIMDW) Stock Price & Analysis
Ainos, Inc. (AIMDW) — price $0.0574 (+29.28%), as of the Nov 19, 2026 trading session.
Educational signal · not a buy or sell recommendation · How to read this
Ainos, Inc. · AIMDW
Ainos, Inc. is a biotechnology company focused on developing innovative medical technologies for point-of-care testing and treatments for various diseases.
Price as of Nov 19, 2026
Key Statistics
Not scored: this is a debt/preferred or other non-common instrument, or its reported market value does not match its share basis.
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $0.0574 | |
| Change on the day | +29.28% | |
| 52-week range | $0.0251 – $0.19 | |
| Shares traded on the day | 599 |
Price & events
Other perspectives
Council score for Ainos (AIMDW): perspectives
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Legends Council
6 lenses, 6 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Nov 19, 2026
Munger's Mindset
Balance Sheet & Valuation · historical
Read on: Apr 30, 2026 · older than the 27 hours refresh window; not a current reading
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
On Apr 30, 2026, the Munger lens read the price at that time as fairly valued against its own estimate of value.
Readings on this page are from Nov 20, 2026, except a card that shows its own read date.
What is Ainos (AIMDW), and what does it report?
Short answer · as of
A current FMP business description is unavailable; the listing and provider classification below are the available identity facts. Ainos, Inc. (AIMDW) is the company analyzed here. It employs 41 people and is led by Chun-Hsien Tsai. In Q2 FY2026 it reported revenue of $152 and net income of -$5M.
What do the latest results show for Ainos (AIMDW)?
Short answer · as of
The most recent reported quarter, Q2 FY2026, carried revenue of $152.
Quarterly income statement — 4 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Q2 FY2026 | $152 | -$5M | -$0.62 (diluted) |
| Q1 FY2026 | $161 | -$2M | -$0.41 (diluted) |
| Q4 FY2025 | $11,120 | -$4M | -$0.85 (diluted) |
| Q3 FY2025 | $2,167 | -$3M | -$0.64 (diluted) |
What are the financial strengths and risks for Ainos (AIMDW)?
Short answer · as of
The distress and quality screens read Altman Z -8.15 · Piotroski F 5. Trailing ratios: ROA -73.9% · current ratio 0.13 · free-cash-flow yield -95.1%.
The records behind this page
Insider activity
Form 4 records via FMP · Of the newest 100 records, those within the last 180 days, newest dated Jun 5, 2026
- Transactions
- 7
- Identified insiders
- 4
- Purchases
- 4
- Sales
- 3
- Other transactions
- 0
Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.
Who holds the shares?
Institutional ownership reported through 13F filings.
Tracked investors
Which of the 16 named investors we follow held AIMDW in their latest 13F filing, and what they did against the filing before it.
None of the 16 tracked investors reported AIMDW in their latest 13F filing.
How to read these figures
These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.
What has been published about Ainos (AIMDW)?
- Ainos Reports Third Quarter 2026 Results and Highlights Expanding AI Nose Commercial Momentum
- Ainos Announces AI Nose Platform Hits Over 3B Chemical Data Points
- Ainos, Inc. (NASDAQ:AIMDW) Sees Significant Drop in Short Interest
- Ainos Completes Required Data Delivery And Technology Transfer Under Its VELDONA License Deal For $600K Initial License Payment
Investor Questions: AIMDW Stock
These answers are editorial: 1 of these 1 answer is drawn from the AIMDW research dossier (written Jun 14, 2026 by gpt-4o-mini). Figures in this section are not part of the source register.
What are the main risks for AIMDW?
Ainos, Inc. faces several risks, including regulatory hurdles that could impact product approvals and market entry. Financial instability is a concern due to negative profit margins and a small market capitalization, which may limit growth opportunities.
Machine-generated analysis by Stock Expert AI — model gpt-4o-mini, generated Jun 14, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources: the source register lists the 13 figures on this page — 8 from Financial Modeling Prep (FMP) and 5 with no recorded source. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.
Publication details and research sources
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com